High serum lactate dehydrogenase level predicts short survival after vincristine-doxorubicin-dexamethasone (VAD) salvage for refractory multiple myeloma

American Journal of Hematology

Volumn 65, Issue 2, 2000, Pages 132-135

  Suguro, Miyuki ^a   Kanda, Yoshinobu ^a   Yamamoto, Rie ^a   Chizuka, Aki ^a   Hamaki, Tamae ^a   Matsuyama, Tomohiro ^a   Takezako, Naoki ^a   Miwa, Akiyoshi ^a   Togawa, Atsushi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

LDH; Multiple myeloma; Prognostic factor; Refractory; VAD

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; LACTATE DEHYDROGENASE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOGRAFT; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; LABELING INDEX; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MULTIPLE MYELOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; TUMOR VOLUME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DOXORUBICIN; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SALVAGE THERAPY; SURVIVAL RATE; VINCRISTINE;

EID: 0033824213     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-8652(200010)65:2<132::AID-AJH7>3.0.CO;2-L     Document Type: Article

References (12)

1. The treatment of multiple myeloma
2. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
3. Why better prognostic factors for multiple myeloma are needed?
4. 2 microglobulin produce a simple and powerful myeloma staging system
5. 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma
6. Effective treatment of advanced multiple myeloma refractory to alkylating agents
7. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities
8. High-dose intravenous melphalan: A review
9. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
10. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma
11. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma
12. High-dose melphalan with autotransplantation for refractory multiple myeloma: Results of a Southwest Oncology Group Phase II Trial